Added to YB: 2026-08-11
Pitch date: 2026-07-08
RXRX [bullish]
Recursion Pharmaceuticals, Inc.
-11.68%
current return
Author Info
Outlier Capital is where I share my highest-conviction ideas, portfolio updates, and investment research. Sign up for the newsletter.
Company Info
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Market Cap
$1.7B
Pitch Price
$3.73
Price Target
36.00 (+1018%)
Dividend
N/A
EV/EBITDA
-2.78
P/E
-3.15
EV/Sales
22.75
Sector
Biotechnology
Category
growth
Healthcare & Biotechnology AI Thesis (I) – 5 Stocks with Credible 10x+ Potential: Recursion Pharmaceuticals (RXRX) – AI-Enabled Biotechnology Drug Discovery Platform
RXRX: AI-native TechBio drug discovery platform (Recursion OS) mapping biology at scale across oncology, rare disease, neuro, immunology. ~$3.6/share, ~$1.9B mcap. 10x thesis on clinical validation, pharma partnerships, licensing re-rating. Risks: trial outcomes, cash burn, scale-up.
Read full article (1 min)